As of July 1, any patient starting treatment with Androcur or his generics must be informed of the risk of a tumor linked to these drugs and benefit from a brain imaging examination, according to the Medicines Agency (ANSM). These drugs are used in particular in the management of hair disorders in women. In August 2018, a study showed that they increased the risk of developing meningioma - the most often benign brain tumor - when they are taken in the highest doses.

"This information mainly concerns women because cyproterone acetate, the active ingredient for these drugs, is a minority prescribed to men, especially for prostate cancer and sexual deviations (chemical castration for pedophilia and/or repeated rapes)", explains Dr. Jean-Michel Race, endocrinologist at the ANSM.